GSK3B and myotonic dystrophy type 1: Recent clinical investigations have successfully utilized unbiased proteomic profiling to identify dysregulated proteins in DM1 fibroblasts, including CAPN1 and CTNNB1, which are modulated by GSK3β, thereby demonstrating the clinical utility of proteomics for disease monitoring (Grande et al., 2021).